Rifaximin targets the beta subunit of bacterial DNA-dependent RNA polymerase, an enzyme required to synthesize RNA. By binding this subunit, it interrupts the transcription process and limits production of bacterial RNA, which suppresses growth in susceptible organisms. This molecular target explains why pharmacologic activity depends on bacterial susceptibility rather than simply intestinal drug presence.
Limited absorption keeps comparatively more rifaximin within the gastrointestinal tract, where the drug is intended to act for bacterial disorders. At the same time, comparatively low systemic exposure becomes relevant when assessing safety and potential drug interactions. Pharmacologic evaluation must therefore consider both local intestinal activity and the amount reaching systemic circulation.
Response depends on whether target bacteria are susceptible to rifaximin and whether the clinical disorder matches an indication for intestinal treatment. The drug’s rifamycin-class mechanism, local concentration in the gut, limited absorption, and possible resistance all shape how efficacy and safety are interpreted. These factors connect molecular action with clinical outcome.
The relevant treatment context is travelers’ diarrhea caused by noninvasive Escherichia coli. Pharmacology focuses on rifaximin’s intestinal antimicrobial action against the susceptible bacterial component of this disorder, rather than treating travelers’ diarrhea as a single undifferentiated condition. Identifying the stated bacterial cause therefore matters when interpreting appropriate use and expected benefit.
One studied application is reducing recurrence of overt hepatic encephalopathy. In this context, the clinically relevant outcome is prevention of repeated episodes rather than treatment of a gastrointestinal infection described only by symptoms. Pharmacologic assessment therefore considers rifaximin as an intervention associated with recurrence reduction, while its intestinal localization remains an important feature of the drug’s profile.
Rifaximin is studied as an option for managing irritable bowel syndrome with diarrhea, linking its gastrointestinal localization to a disorder characterized in the indication by diarrhea. This use illustrates that the drug’s pharmacology is not limited to an acute bacterial disorder. Evaluation centers on its role in managing this specific IBS presentation.